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Particle size and cholesterol 
content of circulating HDL 
correlate with cardiovascular death 
in chronic heart failure
Albert Teis1,2*, G. Cediel1, N. Amigó3,4,5, J. Julve5,6, J. Aranyó1, J. Andrés‑Cordón1, 
C. Puig‑Jové7, E. Castelblanco5,6,8, F. Gual‑Capllonch1, E. Ferrer‑Sistach1, N. Vallejo1, 
G. Juncà1, J. López‑Ayerbe1, M. De Antonio9, M. Domingo9, E. Santiago‑Vacas9, P. Codina9, 
D. Mauricio2,5,6,8,10, J. Lupón9, Nuria Alonso2,5,11* & A. Bayes‑Genis1,2,12
Evidence regarding any association of HDL‑particle (HDL‑P) derangements and HDL‑cholesterol 
content with cardiovascular (CV) death in chronic heart failure (HF) is lacking. To investigate the 
prognostic value of HDL‑P size (HDL‑Sz) and the number of cholesterol molecules per HDL‑P for 
CV death in HF patients. Outpatient chronic HF patients were enrolled. Baseline HDL‑P number, 
subfractions and HDL‑Sz were measured using 1H‑NMR spectroscopy. The HDL‑C/P ratio was 
calculated as HDL‑cholesterol over HDL‑P. Endpoint was CV death, with non‑CV death as the 
competing event. 422 patients were included and followed‑up during a median of 4.1 (0–8) years. 
CV death occurred in 120 (30.5%) patients. Mean HDL‑Sz was higher in CV dead as compared with 
survivors (8.39 nm vs. 8.31 nm, p < 0.001). This change in size was due to a reduction in the percentage 
of small HDL‑P (54.6% vs. 60% for CV‑death vs. alive; p < 0.001). HDL‑C/P ratio was higher in the 
CV‑death group (51.0 vs. 48.3, p < 0.001). HDL‑Sz and HDL‑C/P ratio were significantly associated with 
CV death after multivariable regression analysis (HR 1.22 [95% CI 1.01–1.47], p = 0.041 and HR 1.04 
[95% CI 1.01–1.07], p = 0.008 respectively). HDL‑Sz and HDL‑C/P ratio are independent predictors of 
CV death in chronic HF patients.
Epidemiological and clinical studies have consistently demonstrated that lower levels of high-density lipopro-
tein (HDL) cholesterol (HDL-C) are independently associated with coronary heart disease (CHD)1,2. However, 
attempts to reduce cardiovascular (CV) risk by increasing circulating levels of HDL-C have been  unsuccessful3–5. 
As a consequence, HDL cardioprotective functions rather than HDL-C quantity has been a new focus of interest.
In the last decade, several studies evaluated the relationship of HDL particles (HDL-P) and their subfractions 
to CV risk. The pool of circulating HDL is comprised of a heterogeneous mixture of lipoprotein particles and it 
has been pointed out that small, dense, protein-rich HDLs appear to display potent atheroprotective properties 
across the HDL subpopulation spectrum, which can be attributed to specific clusters of proteins and  lipids6. Sev-
eral authors demonstrated that HDL-P levels have a better correlation with coronary heart disease, coronary heart 
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disease related mortality, coronary artery disease events, and atherosclerosis progression than do the classical 
lipid profile components such as total cholesterol, triglycerides, or low-density lipoprotein (LDL) cholesterol and 
HDL-C  alone7–16. When focusing on HDL subfractions, mainly reduced levels of small HDL-P were associated 
with CV  outcomes9,17–21. However, only a few studies have been published analyzing HDL-P and its subfractions 
in heart failure (HF) patients. A low concentration of small HDL-P has been associated with 3-month all-cause 
mortality in acute HF  patients22,23. A recently published report describe an inverse gradation of small HDL-P 
levels across no-HF, HF with preserved, and HF with reduced ejection fraction patients and its correlation with 
all-cause mortality and coronary artery disease events in a catheterization lab-based  population24.
Moreover, the cholesterol content per particle has also emerged as a potential CV marker. As estimated by 
the ratio of HDL-C to HDL-P (HDL-C/P ratio), it was associated with increased progression of carotid athero-
sclerosis in a community-based  population16.
Despite these studies, to date no data has been reported regarding the association of HDL-P concentration, 
HDL size, HDL-P subfraction distribution, or the HDL-C/P ratio with CV death in chronic HF. Here we inves-
tigate the prognostic value of HDL-P, mean normalized HDL size (HDL-Sz), and the HDL-C/P ratio for CV 
death in patients with ambulatory chronic HF.
Material and methods
Study population and outcomes. Ambulatory patients referred to a structured multidisciplinary HF 
unit of a tertiary university hospital, with an available baseline blood sample, were included from May 2006 to 
April 2014. Patients were considered for the study regardless of HF etiology. All patients were seen regularly in 
follow-up visits at the HF unit. The clinical evaluation and treatment of patients were directed by the responsible 
physician according to a unified protocol, medical criteria, and current clinical practice  guidelines25. Baseline 
blood samples were obtained between 09:00 h and 12:00 h and were stored at − 80 °C without previous freeze–
thaw cycles. Clinical echocardiograms were also performed at baseline by imaging expert cardiologists in dedi-
cated cardiac echocardiographers (Philips iE33; Philips, The Netherlands) as part of routine clinical practice. 
Assessments of left ventricular dimensions and function were performed as recommended in  guidelines26,27. 
Follow-up visits included a minimum of 1 visit with a nurse every 3 months and 1 visit with a physician every 
6 months. The vital status and cause of death (if present) were checked every 3 months. If a patient did not come 
to a scheduled visit, telephone contact with the patient or patient’s relatives was attempted. If contact was not 
possible and death was not certified by clinical records from other hospital wards, the emergency department, or 
general practitioners, vital status was checked from registries of the Spanish Health Systems. Cause of death was 
adjudicated by the physicians once all available records were reviewed.
The primary endpoint of the study was CV death, defined as mortality due to HF, myocardial infarction, 
sudden cardiac death, stroke, or secondary to a cardiovascular procedure. Death by unknown cause was an 
exclusion criteria for the study.
During the baseline visit, patients provided written informed consent for the study. The Local Ethics Com-
mittee of Hospital Germans Trias approved the study (code: EO 10-076). The study was performed in compliance 
with the law protecting personal data, in accordance with the international guidelines on clinical investigation 
of the World Medical Association’s Declaration of  Helsinki28.
Lipoprotein analysis by 1H nuclear magnetic resonance spectroscopy. Serum concentrations of 
triglyceride, cholesterol, HDL-C, the three subclasses (large, medium and small) of HDL particle concentration, 
and HDL-Sz were assessed at baseline using a novel advanced lipoprotein test based on 2D diffusion-ordered 1H 
nuclear magnetic resonance (NMR) spectroscopy. A 250-μL aliquot of serum from each patient was shipped on 
dry ice to Biosfer Teslab (Reus, Spain) for lipoprotein analysis using the Liposcale Test. Cut off values for large, 
medium and small HDL were 9–13 nm, 8.2–9 nm and < 8.2 nm,  respectively29.The variation coefficients for the 
number of particle ranged 2% and 4%, and for particle sizes were lower than 0.3%. The total particle count and 
percentage of total HDL-P constituted by each subfraction were also assessed. The HDL-C/P ratio was calcu-
lated as an estimate of cholesterol content of the HDL  particles16. To calculate the ratio, units of HDL-C were 
transformed to μmol/L.
Statistical analysis. Categorical variables are expressed as the absolute number and percentages. Continu-
ous variables are expressed as means ± SD or medians (quartiles Q1–Q3) for normal and non-normal distribu-
tions, respectively. Data distributions were assessed with normal Q–Q plots. Differences between groups were 
determined using the chi-squared test, Student’s t test, Mann–Whitney U test, Kruskal–Wallis test, and means 
comparison (ANOVA), as appropriate. To evaluate the association of candidate variables with CV death, uni-
variable and multivariable Cox regression analyses were performed with CV death as the dependent variable. 
Multivariable analyses using a stepwise selection method (backward elimination, removing all variables with a 
p value > 0.05) were performed and included the significant covariates from the univariable analysis and other 
relevant clinical variables (age, sex, body mass index, diabetes, arterial hypertension, vasculopathy, ischemic eti-
ology, New York Heart Association [NYHA] functional class III-IV, estimated glomerular filtration rate [eGFR], 
hemoglobin, N-terminal prohormone of brain natriuretic peptide [NT-ProBNP], LDL particles, and treatment 
with angiotensin-converting enzyme inhibitors [ACEi], angiotensin receptor blockers [ARB], beta blockers, 
statins, and implantable cardioverter-defibrillators [ICD]). A competing risk strategy using the Fine and Gray 
method was adopted, considering non-CV death as a competing event. All lipid variables were standardized 
and, accordingly, the resulting hazard ratios reflect a 1-SD change in the given parameter. Survival curves were 
generated from the full model using tertiles of HDL-Sz and the HDL-C/P ratio. Given the known association of 
HDL-P with inflammatory status, additional sensitivity analysis was performed, including in the initial model 
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the glycoprotein (Gly) A, Gly-B, and Gly-F levels, which are three validated, composite 1H-NMR spectroscopy-
derived markers of systemic  inflammation30–33. Considering that the metabolic profile could change during dis-
ease progression, a secondary analysis was performed, according to NYHA functional class. Finally, considering 
the high prevalence of ischemic etiology in our cohort, the interaction between HDL-Sz and the HDL-C/P ratio 
with ischemic etiology was assessed, and found not significant in any case (p = 0.741 and p = 0.809, respectively). 
Moreover, the interaction between HDL-Sz and the HDL-C/P ratio with HF and preserved or reduced ejection 
fraction was assessed, being not significant in any case (p = 0.818 and p = 0.911, respectively).
Statistical analyses were performed using STATA V.13.0 (College Station, Texas, USA). A two-sided p < 0.05 
was considered significant.
Results
Clinical characteristics. A total of 422 patients were included. The baseline characteristics of the subjects 
are listed in Table 1. The main causes of HF included ischemic heart disease (48.1%), dilated cardiomyopathy 
(15.9%), and hypertensive cardiomyopathy (10.2%) (Table 2). As compared with survivors patients, CV death 
patients were older (73.6 vs. 61.4  years; p < 0.001), with higher prevalence of hypertension, (76.7% vs. 59%; 
p = 0.001), peripheral vasculopathy (25% vs. 9%; p < 0.001), ischemic heart disease (65% vs. 36.5%; p = 0.001), 
and atrial fibrillation (32.5% vs. 16.6%; p = 0.003). They also presented with worse baseline NYHA functional 
class (NYHA III-IV 33.3% vs. 13.1%; p < 0.001), eGFR (45.9 ± 25.5 vs. 75.3 ± 36.0 mL/min/1.73  m2; p < 0.001) and 
higher NT-proBNP levels (3949 [1765–7228] vs. 1103 [442–2544] pg/mL; p < 0.001). No differences in left ven-
tricular ejection fraction were observed among groups. Interestingly, CV death patients received a lower propor-
tion of beta blockers (88.3% vs. 95%; p = 0.020), ACEi or ARB (76.7% vs. 91.9%; p < 0.001), or mineralcorticoid 
receptor antagonists (59.2% vs. 70.3%; p = 0.037), but required more loop diuretics (97.5% vs. 82.9%; p < 0.001). 
Statins were used slightly more in the living population (74.2% vs. 82.8%; p = 0.030). Moreover, less ICD therapy 
was used in the CV death patients (10.0% vs. 24.7%; p < 0.001).
NMR spectroscopy lipoprotein profiling. Serum concentrations of total triglycerides, total cholesterol, 
HDL-Sz, HDL subfraction particle numbers, and the calculated HDL-C/P ratio are listed in Table 1. Total choles-
terol and LDL cholesterol were lower in the CV death group in comparison with the living patients (184.9 ± 30.5 
vs. 201.3 ± 40.8 and 103.4 ± 23.2 vs. 115.3 ± 29.8 respectively; both p = 0.001). No differences in HDL-C levels 
or in the number of HDL-P across groups were observed, but HDL-Sz was bigger in the CV death group than 
in the living patients (8.39 ± 0.17 nm vs. 8.31 ± 0.11 nm, p < 0.001). This change in size was mainly produced by 
a decrease in the percentage of small HDL-P (54.6% and 60% for CV death and living patients, respectively; 
p < 0.001), with a consequent proportional variation in the percentage of medium HDL-P (Fig. 1). Additionally, 
the HDL-C/P ratio, an estimator of the degree of cholesterol content of the HDL particles, was higher in CV 
death patients (51.0 ± 6.9 vs. 48.3 ± 4.6 for CV death and survivors respectively; p < 0.001).
Correlations of HDL-Sz and the HDL-C/P ratio with HDL-C and levels of Gly-A, Gly-B, and Gly-F were 
assessed. We found weak but statistically significant correlations of HDL-C with HDL-Sz  (r2 = − 0.28; p < 0.01) 
and the HDL-C/P ratio  (r2 = 0.24; p < 0.01). The correlation of study variables with markers of systemic inflamma-
tion revealed a weak but statistically significant inverse correlation of HDL-Sz with Gly-A  (r2 = − 0.28, p < 0.01), 
Gly-B  (r2 = − 0.08, p = 0.09), and Gly-F  (r2 = − 0.35, p < 0.01). For the HDL-C/P ratio, a modest inverse correlation 
was found with Gly-A  (r2 = − 0.64, p < 0.01) and Gly-F  (r2 = − 0.67, p < 0.01), and a weak inverse correlation with 
Gly-B  (r2 = − 0.26, p = 0.07).
Association of HDL‑Sz and HDL‑C/P ratio with cardiovascular death. During a median follow-up 
of 4.1 (0–8) years, the primary endpoint occurred in 120 patients (30.5%). Main causes of CV death were HF 
(59.2%), sudden cardiac death (18.3%), myocardial infarction (9.2%), and stroke (1.7%). Other causes of death 
corresponded to 11.6% of cases.
As shown in Table 3, a multivariable competing-risk regression analysis demonstrated that both HDL-Sz 
and the HDL-C/P ratio were independent predictors of the occurrence of CV death during follow-up (HR 1.21, 
95% CI 1.01–1.47; p = 0.041 and HR 1.04, 95% CI 1.01–1.07; p = 0.008, respectively). Considering the reported 
biological interaction between HDL function and inflammatory status, we performed an additional sensitivity 
analysis, adding Gly-A, Gly-B, and Gly-F to the initial model, with consistent results (HR 1.22, 95% CI 1.01–1.47; 
p = 0.041 and HR 1.04, 95% CI 1.01–1.47; p = 0.008; for HDL-Sz and the HDL-C/P ratio, respectively). Adjusted 
survival curves were generated using tertiles of HDL-Sz and the HDL-C/P ratio, showing increased risk of CV 
death over time for the higher tertiles of both variables (Fig. 2).
The dispersion of HDL-Sz and HDL-C/P ratio values was also represented, and the total cohort was divided 
into four equally sized groups accounting for HDL-Sz and HDL-C/P median values (8.32 nm and 49.13, respec-
tively) (Supplementary material, Fig. S1). Cases with increased HDL-Sz and highly cholesterol-loaded HDL-P 
were at higher risk of CV death (HR 1.94, 95% CI 1.28–2.96; p = 0.002) (Fig. 3).
Finally, we performed an additional regression analysis according to NYHA functional class evidencing that 
the association of the variables of interest with the outcome of the study remains only significant in the subgroup 
of patients with NYHA functional class III-IV and approaching a level of significance for HDL-Sz in patients 
with NYHA functional class I-II (Supplementary material, Table S1).
Discussion
In this study, circulating particle concentrations of HDL and its subfractions were quantified using 1H-NMR 
spectroscopy in a real-life chronic out-patient clinic HF cohort with exquisite long-term clinical follow-up of 
the patients. We observed significant derangements in mean HDL-Sz and the HDL-C/P ratio in those with CV 
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Table 1.  Baseline characteristics of patients. Results expressed as mean ± SD for quantitative variables and 
n (%) for categorical unless otherwise indicated. COPD chronic obstructive pulmonary disease, BMI body 
mass index, BSA body surface area by Mosteller formula, HR heart rate, AF atrial fibrillation, LBBB left 
bundle branch block, LVEF left ventricular ejection fraction, LVEDd left ventricular end-diastolic diameter, 
Hb hemoglobin, eGFR estimated glomerular filtration rate calculated by Cockoft–Gault formula, ACEi 
Angiotensin Converting Enzyme Inhibitor, ARB Angiotensin II receptor blockers, MRA mineralcorticoid 
receptors antagonists, ICD Implantable Cardiac Defibrillator, CRT Cardiac Resyncronization, NMR nuclear 
magnetic resonance, TG triglycerides, HDL-Sz mean normalized HDL particle size, LDL-C LDL cholesterol, 
HDL-C HDL cholesterol. *Basal Glucose levels only available in 336 patients (in 101 CV death, 66 non-CV 





CV death Non-CV death
n = 422 n = 120 n = 80 n = 222
Age, years 67.2 ± 13.4 73.6 ± 10.1 73.7 ± 9.9 61.4 ± 13.4  < 0.001
Male 312 (72.7) 86 (71.7) 60 (75) 161 (72.5) 0.869
Hypertension 284 (67.3) 92 (76.7) 61 (76.3) 131 (59) 0.001
Diabetes 191 (45.3) 61 (50.8) 41 (51.2) 89 (40) 0.080
Hypercholesterolemia 275 (65.2) 79 (65.8) 56 (70) 140 (63) 0.525
COPD 66 (15.6) 23 (19.2) 17 (21.3) 26 (11.7) 0.060
Vasculopathy 66 (15.6) 30 (25.0) 16 (20) 20 (9)  < 0.001
NYHA Class III–IV 91 (21.6) 40 (33.3) 22 (27.5) 29 (13.1)  < 0.001
BMI 27.38 ± 4.8 26.88 ± 5.00 27.11 ± 4.42 27.73 ± 4.83 0.250
HR, bpm 69.8 ± 14.8 72.8 ± 14.7 69.6 ± 15.0 68.2 ± 14.7 0.025
Atrial fibrillation 96 (22.7) 39 (32.5) 20 (25) 37 (16.6) 0.003
LBBB 53 (12.6) 17 (14.2) 6 (7.5) 30 (13.5) 0.312
LVEF, % 35.6 ± 14.2 36.1 ± 15.5 37.5 ± 14.7 34.6 ± 13.2 0.270
LVEDd, mm 59.9 ± 9.0 59.3 ± 9.6 58.7 ± 8.5 60.5 ± 8.9 0.227
Blood tests
Hb, g/dL 12.7 ± 1.8 12.1 ± 1.7 12.2 ± 1.5 13.2 ± 1.8  < 0.001
Glucose, mg/dL* 120.15 ± 3.0 118.05 ± 5.7 126.11 ± 5.4 119.1 ± 4.4 0.490
Sodium, mmol/L 137.9 ± 3.5 137.7 ± 3.94 138.1 ± 3.1 138.0 ± 3.4 0.706
Potassium, mmol/L 4.24 ± 0.03 4.28 ± 0.05 4.21 ± 0.06 4.23 ± 0.03 0.587
eGFR, mL/min/1.73m2 62.3 ± 34.8 45.9 ± 25.5 50.9 ± 29.1 75.3 ± 36.0  < 0.001
NT-proBNP, pg/mL [median (Q1-Q3)] 1811 (735–4414) 3949 (1765–7228) 2921 (1027–5074) 1103 (442–2544)  < 0.001
Treatment at baseline
Betablockers 389 (92.2) 106 (88.3) 72 (90) 211 (95) 0.020
ACEi/ARB 360 (85.3) 92 (76.7) 64 (80) 204 (91.9)  < 0.001
MRA 279 (66.1) 71 (59.2) 52 (65) 156 (70.3) 0.037
Loop diuretic 373 (88.4) 117 (97.5) 72 (90) 184 (82.9)  < 0.001
Statins 329 (78) 89 (74.2) 56 (70) 184 (82.8) 0.030
ICD 70 (16.6) 10 (10.0) 3 (3.8) 55 (24.8)  < 0.001
CRT 53 (12.6) 13 (10.8) 5 (6.3) 35 (15.8) 0.071
1H-NMR lipid biomarkers
Total TG, mg/dL 129.0 ± 54.4 116.9 ± 47.8 131.4 ± 49.4 134.7 ± 58.6 0.014
Total cholesterol, mg/dL 195.2 ± 38.0 184.9 ± 30.5 193.8 ± 37.0 201.3 ± 40.8 0.001
LDL-C, mg/dL 110.6 ± 27.9 103.4 ± 23.2 108.7 ± 26.9 115.3 ± 29.8 0.001
HDL-C, mg/dL 48.6 ± 10.4 49.2 ± 9.9 47.3 ± 9.8 48.7 ± 10.9 0.436
HDL-Sz, nm 8.34 ± 0.14 8.39 ± 0.17 8.36 ± 0.15 8.31 ± 0.11  < 0.001
HDL particle number, µmol/L (% over total)
Total 25.7 ± 5.4 (100%) 25.2 ± 5.1 (100%) 25.1 ± 5.3 (100%) 26.2 ± 5.7 (100%) 0.133
Large 0.3 ± 0.05 (1.2%) 0.3 ± 0.1 (1.2%) 0.3 ± 0.1 (1.2%) 0.3 ± 0.1 (1.2%) 0.743
Medium 10.2 ± 2.0 (41,0%) 10.7 ± 1.9 (44.2%) 10.3 ± 1.9 (42.4%) 9.9 ± 2.0 (38.8%) 0.002
Small 15.2 ± 4.9 (57,7%) 14.2 ± 5.0 (54.6%) 14.5 ± 4.9 (56.4%) 16.0 ± 4.7 (60.0%) 0.002
HDL-C/P ratio 49.2 ± 5.9 51.0 ± 6.9 49.2 ± 6.6 48.3 ± 4.6  < 0.001
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CV death Non-CV death
n = 422 n = 120 n = 80 n = 222
Ischemic 203 (48.1) 78 (65.0) 44 (55) 81 (36.5)
 < 0.001
DCM 67 (15.9) 11 (9.2) 9 (11.3) 47 (21.2)
Hypertensive 43 (10.2) 10 (8.3) 10 (12.5) 23 (10.4)
Alcoholic 22 (5.2) 0 3 (3.8) 19 (8.5)
Drugs/chemotherapy 14 (3.3) 1 (0.8) 3 (3.8) 10 (4.5)
Valve disease 33 (7.8) 14 (11.7) 6 (7.5) 13 (5.8)
Other 21 (5.0) 3 (2.5) 5 (6.3) 13 (5.8)
HCM 8 (1.9) 2 (1.7) 0 6 (2.7)
Non-compaction 5 (1.2) 0 0 5 (2.2)
Amyloid 3 (0.7) 1 (0.8) 0 2 (0.9)
Peripartum 2 (0.5) 0 0 2 (0.9)
Tachycardiomyopathy 1 (0.2) 0 0 1 (0.4)
Figure 1.  Distribution of HDL particles according to their size in survivors and patients who suffered 
cardiovascular death. HDL-P HDL particle, CV cardiovascular.
Table 3.  Univariable and multivariable Cox Regression Analysis of the associations between HDL-Sz and 
HDL-C/P ratio with cardiovascular death. Hazard ratios for HDL-Sz reflect 1 SD change in a given measure. 
Model 1 Adjusted for age, sex, BMI, diabetes, arterial hypertension, vasculopathy, ischemic etiology, NYHA 
functional class III-IV, eGFR, Hemoglobin, NT-ProBNP, LDL-P and treatment with ACEi/ARB, Betablockers, 
statins and ICD. Model 2 Adjusted for Model 1 plus glycoprotein (Gly)-A, Gly-B and Gly-F. *Other 
independent predictors of the outcomes in these models besides HDL-Sz or HDL-C/P were age, ischaemic 
etiology and NT-proBNP.
HDL-Sz HDL-C/P ratio
HR (95% CI) P value HR (95% CI) P value
Unadjusted 1.36 (1.16–1.58)  < 0.001 1.06 (1.03–1.09)  < 0.001
Multivariable adjustment
Model 1 1.21 (1.01–1.47)* 0.041 1.04 (1.01–1.07)* 0.008
Model 2 1.22 (1.01–1.47)* 0.041 1.04 (1.01–1.07)* 0.008
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Figure 2.  Survival curves showing the probability over time to observe a cardiovascular death across Tertiles 
of HDL-Sz and HDL-C/P ratio. Survival curves showing the probability over time to observe a cardiovascular 
death across Tertiles of normalized mean HDL-P size (HDL-Sz) and HDL-C/P ratio, adjusted for age, sex, 
BMI, diabetes, arterial hypertension, vasculopathy, ischemic etiology, NYHA functional class III–IV, eGFR, 
Hemoglobin, NT-ProBNP and treatment with ACEi/ARB, Betablockers, statins and LDL-P and ICD. Statistical 
significance (p < 0.05) denoted as follows: *significant difference in CV death between the highest and lowest 
tertiles; ¶significant difference in CV death between the highest and middle tertiles. HDL-C/P HDL cholesterol 
over HDL particle ratio, HDL-Sz normalized mean HDL size.
Figure 3.  Survival curves showing the probability over time to observe a cardiovascular death according to the 
HDL-C/P ratio and normalized mean HDL-P size (HDL-Sz). HDL-C/P ratio HDL cholesterol over HDL particle 
ratio, HDL-Sz normalized mean HDL particle size.
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death as compared with survivors after comprehensive multivariable adjustment. Changes in mean HDL-Sz were 
mainly due to a decrease in the proportion of small HDL-P rather than an increase in large HDL-P. Moreover, the 
degree of cholesterol content of the HDL, represented by the HDL-C/P ratio, was increased in those CV death 
patients. We observed that HDL-Sz and elevated levels of cholesterol-overloaded HDL, understood as the HDL 
cholesterol content per particle (HDL-C/P ratio), were independently associated with the increased risk of CV 
death in HF patients. Overall, these findings suggest that alterations in the distribution among HDL subfractions 
and the degree of its cholesterol content are important markers, beyond total cholesterol or HDL-C levels, for 
CV death in out-patient clinic chronic HF patients.
To date, evidence on association of HDL-P and its subfractions in HF patients is scarce, with no data from 
real-life chronic out-patient HF population. Potočnjak et al. and Degoricija et al. identified inverse associations 
of total HDL-P and levels of small HDL-P with very short (3-month) survival in patients hospitalized with acute 
 HF22,23. Hunter et al. found an inverse gradient association of HDL-P count and small HDL-P with all-cause 
mortality and coronary artery disease events in no-HF, HF with preserved and HF with reduced ejection fraction 
patients in a cath-lab based  population24. As in those reports, we also found that the size of HDL (HDL-Sz) and 
percentage of small HDL-P were crucial and associated with adverse events, increasing the importance of this 
marker in the HF population. However, we did not observe any difference in total HDL-P count between CV 
death and survivors, contrary to the other groups’ results. One explanation is that our cohort differs from both of 
their’s, being more representative of real-life chronic HF, with lower overall total HDL-P count across the entire 
cohort, regardless of its future prognosis. Although the comparison must be cautious because different 1H-NMR 
spectroscopy tests were used, the total HDL-P count in our cohort is also lower as compared with the HF with 
reduced ejection fraction subgroup of Hunter et al.’s population (25.7 ± 5.4 vs. 27.2 ± 6.2, for our entire cohort vs. 
Hunter et al.’s cohort). Both groups showed no differences in total cholesterol or HDL-C between alive and dead 
patients, emphasizing the importance of HDL subfraction analysis over total cholesterol or HDL-C in HF. In 
our study, no significant differences in serum HDL-C were observed between survivors and CV death patients; 
however, total cholesterol concentrations were lower in dead patients. One explanation is that our cohort cor-
responds to a real-life chronic HF population, and CV death patients could present with lower total cholesterol 
levels due to more severe and evolved HF process. The cholesterol paradox in HF has been reported previously 
and has been related to  cachexia34,35. In fact, those with CV death were older, presented with worse NYHA class, 
higher NT-proBNP levels, more tachycardia, more incidence of atrial fibrillation and required more loop diuret-
ics. As a consequence of their worse clinical status, less beta blocker, ACEi, ARB, or mineralcorticoid receptor 
antagonist treatment was given. In keeping with this, statins were used slightly less in the CV death population 
as compared with the survivors. However, statin treatment was included in all the multivariate models, and the 
association of HDL-Sz and the HDL-C/P ratio with CV death remained significant.
The HDL-C/P ratio as a surrogate of cholesterol content of HDL-P was previously reported by Qi et al.16 and 
later explored by Amigó et al.36. The average cholesterol content per particle reflects the HDL particle distribution, 
being higher in larger HDL particles, as while the size increases linearly, the cholesterol content increases with 
a cubic relationship. Qi et al. observed that cholesterol-overloaded HDL-P was independently associated with 
the progression of carotid atherosclerosis in a disease-free population. To our knowledge, the HDL-C/P ratio 
has not previously been explored as a marker of adverse cardiovascular events in HF patients. Interestingly, as 
demonstrated in our study, the HDL-C/P ratio is an independent predictor for CV death regardless of the HDL-Sz 
or HDL-P count in HF. This might suggest that derangements in cholesterol transport of HDL are also critical in 
the prognosis of chronic HF patients and that this parameter might be used as a biomarker to stratify CV death 
risk in this population. An anomalous clearance of HDL-C may be one of the explanations for these findings, 
resulting in a final increase in HDL-C/P ratio despite total HDL-C levels. Given the evidence that medium and 
large subfractions of HDL-P are not reduced, the overall cholesterol efflux appears not to be significantly affected 
in chronic HF patients. However, the final pathophysiological mechanism that could explain these findings should 
be explored in further studies. Finally, we also hypothesized that the decrease in small HDL-P might suggest 
a decline in the cardioprotective activity of HDL, which is mainly mediated by small-sized  HDL6,37. However, 
how these molecular effects can be translated at the clinical level should be confirmed in future investigations.
Strengths and limitations. The strengths of our study are that it is representative of real-life chronic HF 
patients, with an exquisite follow-up. Moreover, the relationship of HDL-Sz and HDL-C/P to CV death was 
not only assessed in a comprehensive multivariate model, but also confirmed after adjustment for additional 
sensitivity analysis to rule out any confusing effect of HDL-P and its subfractions with any inflammatory status 
relevant to HF pathobiology.
This study also has some limitations. A selection bias could be present, as patients were included only if a 
baseline blood sample was available. Although it identifies associations of HDL-Sz and the HDL-C/P ratio with 
CV death, it does not prove a causal role of these derangements with adverse outcomes. However, the results 
align with emerging evidence suggesting an association of mainly small HDL-P with events in HF.
Another limitation is that it is a single-center population, and additional clinical investigations regarding the 
association of HDL-P with CV death in HF should be performed. Although several adjusted multivariate models 
were used, unmeasured confounders may have had an impact on the results.
Finally, apolipoprotein A levels or other standard inflammatory parameters beyond Glycoprotein A, B and 
F were not measured. Any interaction of those with the results is unknown.
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Conclusions
In a chronic out-patient-clinic HF population, significant derangements in mean HDL-P size and HDL-C/P ratio 
were associated with CV death. Changes in mean HDL-Sz were mainly due to a decrease in the proportion of 
small HDL-P subfraction. Those with higher HDL-Sz were in higher risk for CV death. Moreover, the degree of 
cholesterol loading of the HDL, represented by the HDL-C/P ratio, was increased in those with CV death. This 
ratio has not been explored as a marker of adverse cardiovascular events in HF patients to date. These associa-
tions were robust, considering the rigorous multivariable adjustment. These data may help refine risk assessment 
and provide new insights into the complex interaction of HDL and HF pathophysiology. Further investigation 
is needed to elucidate the mechanisms underlying the observed associations and a better understanding of the 
role of HDL subfractions and cholesterol content of these particles in chronic HF.
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